Nanomedicine-induced programmed cell death in cancer therapy: mechanisms and perspectives

The balance of programmed cell death (PCD) mechanisms, including apoptosis, autophagy, necroptosis and others, is pivotal in cancer progression and treatment. Dysregulation of these pathways results in uncontrolled cell growth and resistance t o conventional therapies. Nanomedicine offers a promisin...

Full description

Saved in:
Bibliographic Details
Published in:Cell death discovery 2024-08, Vol.10 (1), p.386-13, Article 386
Main Authors: Luobin, Lin, Wanxin, He, Yingxin, Guo, Qinzhou, Zheng, Zefeng, Liang, Danyang, Wu, Huaqin, Li
Format: Article
Language:English
Subjects:
631/67
692/308/153
692/699/67
Apoptosis
Autophagy
Biochemistry
Biocompatibility
Biomedical and Life Sciences
Cancer therapies
Cell Biology
Cell Cycle Analysis
Cell death
Cell growth
Chemotherapy
Drug delivery
Drug delivery systems
Drug resistance
Life Sciences
Ligands
Light therapy
Medical innovations
Nanomaterials
Nanoparticles
Nanotechnology
Necroptosis
Polyethylene glycol
Quantum dots
Radiation therapy
Review Article
Side effects
Stem Cells
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The balance of programmed cell death (PCD) mechanisms, including apoptosis, autophagy, necroptosis and others, is pivotal in cancer progression and treatment. Dysregulation of these pathways results in uncontrolled cell growth and resistance t o conventional therapies. Nanomedicine offers a promising solution in oncology through targeted drug delivery enabling precise targeting of cancer cells while preserving healthy tissues. This approach reduces the side effects of traditional chemotherapy and enhances treatment efficacy by engaging PCD pathways. We details each PCD pathway, their mechanisms, and innovative nanomedicine strategies to activate these pathways, thereby enhancing therapeutic specificity and minimizing harm to healthy tissues. The precision of nanotechnology in targeting PCD pathways promises significant improvements in cancer treatment outcomes. This synergy between nanotechnology and targeted PCD activation could lead to more effective and less toxic cancer therapies, heralding a new era in cancer treatment.
ISSN:2058-7716
2058-7716
DOI:10.1038/s41420-024-02121-0